Home > Boards > US OTC > Medical - Drugs > Innovation Pharmaceuticals Inc. (IPIX)

"Finally, with the underserved stock option awards, is

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
loanranger Member Profile
Member Level 
Followed By 191
Posts 31,816
Boards Moderated 1
Alias Born 06/30/09
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 11/9/2021 1:45:15 PM
IQST Has Catalysts On Deck That Expose A Valuation Disconnect of Roughly 100% - Here's Why That Gap Should Close InvestorsHub NewsWire - 11/5/2021 10:20:59 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/14/2021 5:01:12 PM
CEO Presenting on the Emerging Growth Conference on October 13 Register Now InvestorsHub NewsWire - 10/11/2021 7:00:00 AM
CEO's Presenting on the Emerging Growth Conference 17 TODAY.  Register Now InvestorsHub NewsWire - 9/29/2021 8:00:00 AM
CLS Holdings, (OTCQB: CLSH) New Joint Venture $19 million Sales 61% Growth InvestorsHub NewsWire - 9/28/2021 7:24:31 AM
Nightfood, Inc. (OTCQB: NGTF) Significant Retail Expansion InvestorsHub NewsWire - 7/21/2021 6:47:54 AM
Innovation Pharma selected for a presentation on experimental COVID-19 therapy Seeking Alpha - 6/18/2021 10:31:54 AM
The Emerging Growth Conference is Today.  Register Now. InvestorsHub NewsWire - 6/9/2021 7:00:00 AM
Patient enrollment reaches 90 percent in Innovation Pharmaceuticals' mid-stage COVID-19 trial Seeking Alpha - 5/27/2021 10:29:46 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/13/2021 8:01:45 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 5/3/2021 12:54:36 PM
Innovation gives update on mid-stage Brilacidin COVID-19 trial Seeking Alpha - 4/5/2021 8:03:34 AM
CLS Holdings, (OTCQB: CLSH) $1.49 million Net Revenue for Feb Highest in Company History InvestorsHub NewsWire - 3/9/2021 6:37:33 AM
Innovation updates on mid-stage Brilacidin COVID-19 trial Seeking Alpha - 3/5/2021 1:07:47 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/22/2021 11:20:39 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 2/17/2021 8:01:12 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/11/2021 4:47:49 PM
CLS Holdings, (OTCQB: CLSH) Record January NET Revenue of $1.48 Million Beating Target InvestorsHub NewsWire - 2/9/2021 6:48:48 AM
CLS Holdings, (OTCQB: CLSH) $17 million Sales, 60% Growth & 5 New Products InvestorsHub NewsWire - 2/2/2021 6:52:54 AM
loanranger Member Level  Saturday, 10/16/21 11:10:47 AM
Re: zandant post# 378890
Post # of 387674 
"Finally, with the underserved stock option awards, is there a predetermined price to buy the shares and if so, what is that price, and is there an expiration date? "

You talking about these?
"Annual Stock Option Awards — The Compensation Committee approved stock option awards under the Plan relating to one million shares of common stock to each independent director and 500,000 shares of common stock to each of the non-independent director and the Company's Senior Vice President, Clinical Sciences and Portfolio Management."

First off, it's funny the LE describes himself as "the non-independent director" versus his proper management title. Like it's a disguise :o)

Different kinds of options get different tax and accounting treatments...too complicated for me. But I do remember that the SEC had something to say about the BIG deal back in the early part of the last decade involving the creation of the Class B (approved by a majority of shareholders comprised of members of both families) and the options that KM and LE granted themselves at the time.

First they filed the 2010 Equity Incentive Plan dated 12/29/10 on 2/2/11, plainly hoping to push the effective date back into 2010.
Suitable for framing: https://www.sec.gov/Archives/edgar/data/1355250/000135525011000003/form8k.htm
(under https://www.sec.gov/Archives/edgar/data/1355250/000135525011000003/0001355250-11-000003-index.htm )

Then they filed a Preliminary Information Statement on 2/8/11 that described the above. The SEC dropped em a note....
Who approved it, by what share counts, what were the circumstances under which the vote took place and even what the heck happened to that reverse split you guys voted on a little while ago? And lots more. But to your question:
"We note that with respect to a stock option granted to a person possessing more than 10%
of the total combined voting power of all classes of stock, the exercise price may not be
less than110% of the fair market value on the date of the grant. Since Dr. Menon and Mr.
Ehrlich each own more than 10% of the combined voting power, please confirm the
exercise price for the options granted to them met or exceeded the 110% requirement. In
this regard, we note the closing price for your common stock in the “pink sheets” for
December 29, 2010 was apparently $0.10 per share and that 110% of this closing price
would equal $0.11 per share. We also note your Form 8-K filed on February 2, 2010
indicates the exercise price for the options as $0.10 per share."

As a result the boys had to bump the exercise up a penny to 11 cents. More of an embarrassment than anything else. I guess my point is that your question about price is a good one. In my opinion they aren't likely to establish a price for the options ahead of the grant and when they do it will be a bare minimum above the then market price. There will be a legally required vesting period (a year or two before exercise) and a holding period for the stock...again, just guessing based on a minimum of experience with such things.

Fear not, it'll all be spelled out in the grant filing. At least it should be. Or in the Form 4s if the jokers file them. Harness has been the most reliable in this regard. LE and the boys on the block are already light a couple filings.

As my dear old grandfather Litvak said (just before they swung the trap), he said "You can't cheat an honest man. Never give a sucker an even break or smarten up a chump."
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences